SERAHealthcare · Medical Devices

SERA Stock Forecast: Sera Prognostics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$2.14

+1.90% on the day

The 4 Wall Street analysts covering Sera Prognostics, Inc. hold a median 12-month price target of $5.5 — +157.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 22 Aug 2026 — in the lower half.

Market cap

$84.4M

Ticker Nerd rank

40 / 100

Median analyst target

$5.50

Analysts covering

Total return, dividends reinvested

+9.2%

−5.7%

YTD

−27.5%

−10.1%

From 52W high

−42.9%

From 52W low

+34.6%

$1.59

$3.75

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

SERA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sera Prognostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

40 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Growth

Revisions

Momentum

Quality

Volatility

Issuance

Value

Size (77): Smaller than most of the companies we track.

Value (18): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SERA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SERA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts

4 Buy0 Hold0 Sell

Low $5.00Median $5.50High $6.00

The green dot is the last close — the median target sits +157.0% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
4 June 2026	Craig-Hallum	Initiates	Buy	$6.00
10 Aug 2023	Citigroup	Maintains	Neutral	—
10 Nov 2022	Citigroup	Maintains	Neutral	—
14 Sept 2022	Berenberg	Initiates	Buy	—
29 Aug 2022	Oppenheimer	Maintains	Outperform	—
27 Apr 2022	Berenberg	Initiates	Buy	—
30 Mar 2022	Citigroup	Downgrade	Neutral	—
19 Nov 2021	Oppenheimer	Initiates	Outperform	—
9 Aug 2021	Citigroup	Initiates	Buy	—
9 Aug 2021	Cowen & Co.	Initiates	Outperform	—
9 Aug 2021	William Blair	Initiates	Outperform	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SERA appears on the weeks it earns a place.

Estimates

SERA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Sera Prognostics, Inc. (SERA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −3.1×
Price / sales: 1206.0×
Price / book: 1.2×
EV / EBITDA: −1.1×

Growth & margins

Revenue growth (YoY): 76.5%
Earnings growth (YoY): −63.2%
Gross margin: −200.0%
Operating margin: −33346.7%
Net margin: −102.5%

Returns & dividend

Return on equity: −45.0%
Return on assets: −23.5%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SERA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
SERASera Prognostics, Inc.	$84.4M	40
RPIDRapid Micro Biosystems, Inc.	$83.7M	32
OMOutset Medical, Inc.	$77.0M	29
LUNGPulmonx Corp.	$93.2M	74
CVRXCVRx, Inc.	$74.7M	34
ECORelectroCore, Inc.	$94.8M	54
HYPRHyperfine, Inc.	$95.7M	56

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sera Prognostics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SERA news & analysis

SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER

PRNewsWire · 19 Aug 2026positive

Sera Prognostics, Inc. announced on August 19, 2026 that Scott Gleason has been appointed Chief Financial Officer, effective August 31, 2026. Gleason brings over 25 years of experience in healthcare, diagnostics, and capital markets to the company.

Why it matters — A new CFO with extensive healthcare and capital markets experience could be significant for SERA watchers given the company's focus on pregnancy biomarker diagnostics and its standing as a publicly traded firm.

Sera Prognostics Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026neutral

Sera Prognostics reported modest second-quarter revenue and discussed progress on payer engagement, Illinois Medicaid policy, clinical evidence, and European regulatory preparations for its PreTRM Test-guided care platform.

Why it matters — SERA watchers would care because the update offers insight into the company's operational milestones and market-access strategy for its core PreTRM test.

Sera Prognostics, Inc. (SERA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

Sera Prognostics, Inc. held its Q2 2026 earnings call, and a transcript of the call has been published by Seeking Alpha. The event covers the company's second-quarter 2026 financial results and management commentary.

Why it matters — A SERA watcher would care because the earnings call transcript provides a record of the company's latest quarterly financial performance and management's discussion of its business.

Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 12 Aug 2026negative

Sera Prognostics reported a Q2 loss of $0.18 per share, wider than both the Zacks Consensus Estimate of a $0.14 loss and the $0.16 loss reported in the same quarter last year. Revenue also fell short of expectations.

Why it matters — The larger-than-expected loss and revenue miss could raise concerns about the company's near-term financial performance and trajectory versus analyst expectations.

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

PRNewsWire · 12 Aug 2026positive

Sera Prognostics announced its financial results for the second quarter ended June 30, 2026. Among recent highlights, the company launched its fourth partnership program in August 2026 to expand implementation of PreTRM Test-guided care through a state-based initiative with a national payer.

Why it matters — SERA watchers would care because the new fourth partnership program signals continued expansion of the company's commercial adoption strategy for the PreTRM test.

FAQ

Frequently asked questions about SERA stock

What is the SERA stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Sera Prognostics, Inc. have a median 12-month price target of $5.5, with estimates ranging from $5 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SERA stock a buy right now?

Of the 4 analysts covering Sera Prognostics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sera Prognostics, Inc. 40 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SERA?

As at 22 Aug 2026, Sera Prognostics, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (77 of 100).

Will SERA stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +157.0% from the last close, and Ticker Nerd's factor model ranks Sera Prognostics, Inc. 40 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SERA stock forecast for 2030?

No analyst covering Sera Prognostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SERA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $6 over the next 12 months.

How has SERA stock performed over the past year?

Sera Prognostics, Inc. returned -10.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sera Prognostics, Inc. do?

Sera Prognostics Inc. is a biotechnology company specializing in predictive diagnostic tests for pregnancy-related complications.

What is the latest news on SERA?

The most recent item we track (PRNewsWire, 19 Aug 2026): "SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER". Sera Prognostics, Inc. announced on August 19, 2026 that Scott Gleason has been appointed Chief Financial Officer, effective August 31, 2026. Gleason brings over 25 years of experience in healthcare, diagnostics, and capital markets to the company.

Company

About Sera Prognostics, Inc.

Sera Prognostics Inc. is a biotechnology company specializing in predictive diagnostic tests for pregnancy-related complications. The company focuses on developing and commercializing blood-based tests that help assess a pregnant patient’s risk for conditions such as preterm birth, preeclampsia, and other adverse outcomes. By applying proteomic and analytic technologies, Sera Prognostics aims to provide clinicians with actionable risk assessments that can support more informed decisions around monitoring, intervention, and allocation of maternal-fetal care resources. Its products are designed to be used within routine prenatal care, serving obstetric practices, health systems, and payers that seek to improve maternal and neonatal health outcomes while managing costs associated with high-risk pregnancies. Founded in 2008 and headquartered in Salt Lake City, Utah, Sera Prognostics operates at the intersection of diagnostics, obstetrics, and population health management within the healthcare and life sciences markets.

CEO Ms. Zhenya Lindgardt M.B.A. · 71 employees · United States · https://www.sera.com